BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26062540)

  • 1. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
    Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
    BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.
    Lana S; U'ren L; Plaza S; Elmslie R; Gustafson D; Morley P; Dow S
    J Vet Intern Med; 2007; 21(4):764-9. PubMed ID: 17708397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
    U'Ren LW; Biller BJ; Elmslie RE; Thamm DH; Dow SW
    J Vet Intern Med; 2007; 21(1):113-20. PubMed ID: 17338158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
    Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
    Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014).
    Batschinski K; Nobre A; Vargas-Mendez E; Tedardi MV; Cirillo J; Cestari G; Ubukata R; Dagli MLZ
    Can Vet J; 2018 Sep; 59(9):967-972. PubMed ID: 30197439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology.
    Marconato L; Chalfon C; Finotello R; Polton G; Vasconi ME; Annoni M; Stefanello D; Mesto P; Capitani O; Agnoli C; Amati M; Sabattini S
    Vet Comp Oncol; 2019 Dec; 17(4):537-544. PubMed ID: 31251441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma.
    Sorenmo K; Samluk M; Clifford C; Baez J; Barrett JS; Poppenga R; Overley B; Skorupski K; Oberthaler K; Van Winkle T; Seiler G; Shofer F
    J Vet Intern Med; 2007; 21(6):1347-54. PubMed ID: 18196746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Doxorubicin with or without Metronomic Cyclophosphamide for Canine Splenic Hemangiosarcoma.
    Matsuyama A; Poirier VJ; Mantovani F; Foster RA; Mutsaers AJ
    J Am Anim Hosp Assoc; 2017; 53(6):304-312. PubMed ID: 28892429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgery and doxorubicin in dogs with hemangiosarcoma.
    Ogilvie GK; Powers BE; Mallinckrodt CH; Withrow SJ
    J Vet Intern Med; 1996; 10(6):379-84. PubMed ID: 8947871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
    Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
    Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004).
    Kim SE; Liptak JM; Gall TT; Monteith GJ; Woods JP
    J Am Vet Med Assoc; 2007 Nov; 231(10):1550-7. PubMed ID: 18021000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of outcome associated with subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21 cases (2001-2006).
    Bulakowski EJ; Philibert JC; Siegel S; Clifford CA; Risbon R; Zivin K; Cronin KL
    J Am Vet Med Assoc; 2008 Jul; 233(1):122-8. PubMed ID: 18593321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.
    Kahn SA; Mullin CM; de Lorimier LP; Burgess KE; Risbon RE; Fred RM; Drobatz K; Clifford CA
    Can Vet J; 2013 Mar; 54(3):237-42. PubMed ID: 23997259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the anti-tumour activity of Coriolus versicolor polysaccharopeptide (I'm-Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma.
    Gedney A; Salah P; Mahoney JA; Krick E; Martins R; Scavello H; Lenz JA; Atherton MJ
    Vet Comp Oncol; 2022 Sep; 20(3):688-696. PubMed ID: 35442554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.
    London CA; Gardner HL; Mathie T; Stingle N; Portela R; Pennell ML; Clifford CA; Rosenberg MP; Vail DM; Williams LE; Cronin KL; Wilson-Robles H; Borgatti A; Henry CJ; Bailey DB; Locke J; Northrup NC; Crawford-Jakubiak M; Gill VL; Klein MK; Ruslander DM; Thamm DH; Phillips B; Post G
    PLoS One; 2015; 10(4):e0124889. PubMed ID: 25923466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma.
    Teske E; Rutteman GR; Kirpenstein J; Hirschberger J
    Vet Comp Oncol; 2011 Dec; 9(4):283-9. PubMed ID: 22077409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timely adjuvant chemotherapy improves outcome in dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy.
    Faroni E; Sabattini S; Guerra D; Iannuzzi C; Chalfon C; Agnoli C; Stefanello D; Polton G; Ramos S; Aralla M; Ciaccini R; Foglia A; Okonji S; Marconato L
    Vet Comp Oncol; 2023 Mar; 21(1):123-130. PubMed ID: 36633399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012).
    Wendelburg KM; Price LL; Burgess KE; Lyons JA; Lew FH; Berg J
    J Am Vet Med Assoc; 2015 Aug; 247(4):393-403. PubMed ID: 26225611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma.
    Borgatti A; Fieberg A; Winter AL; Stuebner K; Taras E; Todhunter D; Masyr A; Rendhal A; Vallera DA; Koopmeiners JS; Modiano JF
    Vet Comp Oncol; 2020 Dec; 18(4):664-674. PubMed ID: 32187827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.
    MacEwen EG; Kurzman ID; Helfand S; Vail D; London C; Kisseberth W; Rosenthal RC; Fox LE; Keller ET; Obradovich J
    J Drug Target; 1994; 2(5):391-6. PubMed ID: 7704483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.